Tigermed IPO Initiation: Trade-Offs
Hangzhou Tigermed Consulting (300347 CH) is a global contract research organisation (CRO). Tigermed is the largest clinical CRO in China with a...
410 Views
Tigermed (泰格医疗) A+H Listing: Hot Deal of the Best China Clinical-CRO Play
Hangzhou Tigermed is a leading China-based CRO company seeking a USD 1 bn H-share listing in Hong Kong. The company was listed on the A-share...
470 Views
Hepalink Pharma IPO Initiation: Take a Chance on Me
Shenzhen Hepalink Pharma Co., Ltd. (002399 CH) is a leading China-based pharmaceutical company with global businesses in pharmaceutical, innovative...
711 Views
Long Pharmaron/Short Wuxi: Take Profit Now, A-Share Pullback the Key Risk
Pharmaron, the second-largest contract research organization (CRO) in China, was listed in Hong Kong on November 28th. The deal was anchored by a...
434 Views
WuXi Biologics Placement: Pushing the Limits
Wuxi Biologics (Cayman) Inc (2269 HK) is a global one-stop biologics services provider and often referred to as CRO (contract research...
465 Views